Literature DB >> 21529958

Evaluation of retinal nerve fiber layer progression in glaucoma a prospective analysis with neuroretinal rim and visual field progression.

Christopher Kai Shun Leung1, Shu Liu, Robert N Weinreb, Gilda Lai, Cong Ye, Carol Yim Lui Cheung, Chi Pui Pang, Kwok Kay Tse, Dennis Shun Chiu Lam.   

Abstract

OBJECTIVE: To evaluate the performance of progression detection and the rate of change of retinal nerve fiber layer (RNFL), neuroretinal rim, and visual field measurements in glaucoma.
DESIGN: Prospective study. PARTICIPANTS: One hundred eight eyes of 70 glaucoma patients.
METHODS: Patients were followed up every 4 months for at least 2.9 years (median, 3.2 years) for measurement of RNFL thickness with the Stratus optical coherence tomograph (OCT) (Carl Zeiss Meditec, Dublin, CA), neuroretinal rim area with the Heidelberg Retinal Tomograph (HRT 3; Heidelberg Engineering, GmbH, Dossenheim, Germany), and visual field with the Humphrey Field Analyzer II (Carl Zeiss Meditec). Linear regression analyses were performed between visual field index (VFI), RNFL, and neuroretinal rim measurements and age, with progression defined when a significant negative trend was detected. The agreement among structural and functional measurements was evaluated with κ statistics. The mean rate of change was estimated with linear mixed modeling. MAIN OUTCOME MEASURES: The agreement on progression detection and the rate of change of RNFL, neuroretinal rim, and VFI measurements.
RESULTS: A total of 1105 OCT, 1062 HRT, and 1099 visual field measurements were analyzed. The agreement of progression detection among the 3 investigations was poor (κ≤0.09). Ten eyes (9.3%; 9 patients) showed progression by average RNFL thickness, 16 (14.8%; 14 patients) by global neuroretinal rim area, and 35 (32.4%; 31 patients) by VFI. Only 1 eye (0.9%) had progression detected by all 3 methods. There were large variations in the rate of change of VFI, average RNFL thickness, and global neuroretinal rim area, with a range between -0.63% and -4.97% per year, -2.32% and -10.12% per year, and -0.61% and -8.48% per year, respectively. The respective mean rate estimates were -1.15% per year (95% confidence interval [CI], -1.56% to -0.73%), -0.70% per year (95% CI, -1.19% to -0.21%), and -1.06% per year (95% CI, -1.56% to -0.55%).
CONCLUSIONS: The agreement of progression detection among RNFL, neuroretinal rim, and visual field measurements was poor, and the rate of RNFL, neuroretinal rim, and visual field progression varied considerably within and between subjects. Given this variability, interpretation of RNFL, neuroretinal rim, and VFI progression always should be evaluated on an individual basis. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21529958     DOI: 10.1016/j.ophtha.2010.12.035

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  47 in total

1.  Glaucoma research community and FDA look to the future, II: NEI/FDA Glaucoma Clinical Trial Design and Endpoints Symposium: measures of structural change and visual function.

Authors:  Robert N Weinreb; Paul L Kaufman
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-10-04       Impact factor: 4.799

2.  Relationship between short-wavelength automatic perimetry and Heidelberg retina tomograph parameters in eyes with ocular hypertension.

Authors:  Christos Pitsas; Dimitrios Papaconstantinou; Ilias Georgalas; Ioannis Halkiadakis
Journal:  Int J Ophthalmol       Date:  2015-10-18       Impact factor: 1.779

3.  What rates of glaucoma progression are clinically significant?

Authors:  Luke J Saunders; Felipe A Medeiros; Robert N Weinreb; Linda M Zangwill
Journal:  Expert Rev Ophthalmol       Date:  2016-05-13

4.  Difference in correspondence between visual field defect and inner macular layer thickness measured using three types of spectral-domain OCT instruments.

Authors:  Kaori Ueda; Akiyasu Kanamori; Azusa Akashi; Yuki Kawaka; Yuko Yamada; Makoto Nakamura
Journal:  Jpn J Ophthalmol       Date:  2014-11-07       Impact factor: 2.447

5.  Comparison of event-based analysis of glaucoma progression assessed subjectively on visual fields and retinal nerve fibre layer attenuation measured by optical coherence tomography.

Authors:  Sushmita Kaushik; Samyak Mulkutkar; Surinder Singh Pandav; Neelam Verma; Amod Gupta
Journal:  Int Ophthalmol       Date:  2014-12-13       Impact factor: 2.031

6.  Patterns of glaucoma progression in retinal nerve fiber and macular ganglion cell-inner plexiform layer in spectral-domain optical coherence tomography.

Authors:  Hae Jin Kim; Jin Wook Jeoung; Byeong Wook Yoo; Hee Chan Kim; Ki Ho Park
Journal:  Jpn J Ophthalmol       Date:  2017-04-03       Impact factor: 2.447

Review 7.  Test-retest variability in structural parameters measured with glaucoma imaging devices.

Authors:  Makoto Araie
Journal:  Jpn J Ophthalmol       Date:  2012-11-09       Impact factor: 2.447

8.  Retinal nerve fiber layer atrophy is associated with visual field loss over time in glaucoma suspect and glaucomatous eyes.

Authors:  Mitra Sehi; Xinbo Zhang; David S Greenfield; Yunsuk Chung; Gadi Wollstein; Brian A Francis; Joel S Schuman; Rohit Varma; David Huang
Journal:  Am J Ophthalmol       Date:  2012-10-01       Impact factor: 5.258

9.  Discrepancy between optic disc and nerve fiber layer assessment and optical coherence tomography in detecting glaucomatous progression.

Authors:  Jong Rak Lee; Kyung Rim Sung; Jung Hwa Na; Kilhwan Shon; Kyoung Sub Lee
Journal:  Jpn J Ophthalmol       Date:  2013-10-05       Impact factor: 2.447

10.  The rate of structural change: the confocal scanning laser ophthalmoscopy ancillary study to the ocular hypertension treatment study.

Authors:  Linda M Zangwill; Sonia Jain; Keri Dirkes; Feng He; Felipe A Medeiros; Gary L Trick; James D Brandt; George A Cioffi; Anne L Coleman; Jeffrey M Liebmann; Jody R Piltz-Seymour; Mae O Gordon; Michael A Kass; Robert N Weinreb
Journal:  Am J Ophthalmol       Date:  2013-03-14       Impact factor: 5.258

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.